首页> 外文期刊>Archives of medical research >5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.
【24h】

5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.

机译:5-氟尿嘧啶和奥沙利铂每周联合放疗治疗局部晚期直肠癌:手术并发症和长期结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: We undertook this study to evaluate early surgical complications and long-term results after preoperative radiotherapy and chemotherapy (RCT) using 5-fluorouracil (5-FU) and oxaliplatin (OXA) for rectal cancer. METHODS: Forty six TNM stage II-III rectal cancer patients were studied, who were given preoperative RT (50.4 Gy/28 fractions) combined with 5-FU (200-225 mg/m(2)/day by continuous venous infusion) and weekly OXA (25-60 mg/m(2)). Major complications and reoperations were recorded overall, whereas outcome analyses were performed only for patients who received the recommended regimen dosage. RESULTS: Forty three patients (M:F, 25:18; median age 59 years) were available for analysis. All patients received the planned RT dose. There were no postoperative deaths; seven patients had early major surgical complications, four requiring re-operation. One additional patient had a second surgical procedure due to a duodenal fistula complicating the resection of an aortic aneurysm performed concomitantly with rectal cancer surgery. At a median follow-up of 49 months, two of the 23 patients treated at the recommended doses developed recurrence (one local, and one local and distant), and two died of cancer progression. Following the Kaplan-Meier method, the estimated 5-year overall and disease-free survival rates were 92 and 89%, respectively. CONCLUSIONS: The preoperative RCT regimen used in the present study incurs a low rate of recurrence with an acceptable surgical morbidity.
机译:背景:我们进行了这项研究,以评估术前使用5-氟尿嘧啶(5-FU)和奥沙利铂(OXA)进行直肠癌放疗和化疗(RCT)后的早期手术并发症和长期效果。方法:对46例TNM II-III期直肠癌患者进行了研究,他们接受术前放疗(50.4 Gy / 28次)与5-FU(200-225 mg / m(2)/天,连续静脉输注)联合应用,每周OXA(25-60 mg / m(2))。总体记录了主要并发症和再次手术,而结果分析仅针对接受推荐方案剂量的患者进行。结果:43例患者(男:女,25:18;中位年龄59岁)可供分析。所有患者均接受了计划的放疗剂量。没有术后死亡; 7例患者有早期重大外科手术并发症,其中4例需要再次手术。另一名患者因十二指肠瘘并发直肠癌手术而切除了主动脉瘤,因此进行了第二次手术。在49个月的中位随访中,以推荐剂量治疗的23例患者中有2例复发(1例局部,1例局部和远处),其中2例死于癌症进展。按照Kaplan-Meier方法,估计的5年总生存率和无病生存率分别为92%和89%。结论:本研究中使用的术前RCT方案可降低复发率,并具有可接受的手术发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号